HIV-associated lipohypertrophy involves GH/IGF-1 axis dysfunction, with GH-releasing hormone (tesamorelin) approved for reducing visceral fat in HIV lipodystrophy — GHRH analog as an HIV metabolic therapy.
Key findingHIV-associated lipohypertrophy involves GH/IGF-1 axis dysfunction, with GH-releasing hormone (tesamorelin) approved for reducing visceral fat in HIV l
What the researchers found
HIV-associated lipohypertrophy involves GH/IGF-1 axis dysfunction, with GH-releasing hormone (tesamorelin) approved for reducing visceral fat in HIV lipodystrophy — GHRH analog as an HIV metabolic therapy.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2011.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Pathogenesis and treatment of HIV lipohypertrophy.
Current opinion in infectious diseases, 24(1), 43-9
Citation
Leung, Vivien L; Glesby, Marshall J. (2011). Pathogenesis and treatment of HIV lipohypertrophy.. Current opinion in infectious diseases, 24(1), 43-9. https://doi.org/10.1097/QCO.0b013e3283420eef